Breast Cancer News

Skip to content
  • Home
  • What Is Breast Cancer?
    • Types of Breast Cancer
    • Breast Cancer Classification
    • Causes of Breast Cancer
      • Breast Tissue Density
      • Risk Factors
    • Signs and Symptoms
      • Breast Lump or Mass
      • Breast or Nipple Pain
      • Breast Swelling & Inflammatory Breast Cancer
      • Nipple or Breast Skin Alterations
      • Nipple Retraction
      • Skin Irritation or Dimpling
    • Diagnosis of Breast Cancer
    • Stages
    • Breast Cancer Statistics
    • Breast Cancer During Pregnancy
  • Treatment
    • Bone-directed Therapy
    • Chemotherapy
    • Surgery
      • Mastectomy
      • Breast Reconstruction
    • Radiation Therapy
    • Targeted Therapy
    • Ado-Trastuzumab Emtansine (Kadcyla)
    • Albumin-Bound Paclitaxel (Nab-Paclitaxel or Abraxane)
    • Anastrozole (Arimidex)
    • Capecitabine (Xeloda)
    • Cyclophosphamide (Clafen, Cytoxan, and Neosar)
    • Docetaxel (Taxotere)
    • Epirubicin Hydrochloride (Ellence)
    • Eribulin (Halaven)
    • Everolimus (Afinitor)
    • Exemestane (Aromasin)
    • Gemcitabine Hydrochloride (Gemzar)
    • Goserelin Acetate (Zoladex)
    • Ixabepilone (Ixempra)
    • Lapatinib Ditosylate (Tykerb)
    • Letrozole (Femara)
    • Lynparza (Olaparib)
    • Nerlynx (Neratinib)
    • Tecentriq
    • Experimental Treatments
      • GBR 1302
      • GMI-1359
  • Columns
    • A Lump in the Road
    • Journeying Toward the Pink Path
    • Protecting the Pecs
    • Chemo and Cocktails: A Young Survivor’s Guide
  • Login
  • COVID-19 Info
    • COVID-19 Updates

High BCL11A Activity Found in Triple Negative Breast Cancer

January 14, 2015January 14, 2015
Maureen Newmanby Maureen Newman

In Breast Cancer News, News.

High BCL11A Activity Found in Triple Negative Breast Cancer

Click here to subscribe to the Breast Cancer News Newsletter!

0
(0)

shutterstock_61648807Researchers from the Wellcome Trust Sanger Institute have identified a new gene linked to triple negative breast cancer (TNBC), which has one of the poorest prognoses and describes 20% of all breast cancers. Finding an association between BCL11A and TNBC is important, as according to study author Dr. Carlos Caldas, “Finding a novel gene that is active in cancer should also help in the search for new treatments.”

Writing in the journal Nature Communications, Dr. Caldas was joined by lead author Dr. Walid Khaled and senior author Dr. Pentao Liu, as well as fellow collaborators at Wellcome Trust Sanger Institute and University of Cambridge. Their article, “BCL11A is a Triple-Negative Breast Cancer Gene with Critical Functions in Stem and Progenitor Cells,” described experiments conducted with humans and mice to discover the presence of overactive BCL11A in up to 38% of basal-like breast cancer (BLBC) tumors. “BCL11A activity stood out because it is so active in triple-negative cancers,” stated Dr. Liu in a news release.

Only a few genetic mutations are associated with TNBC, leading researchers to look for more. “Our understanding of genes that drive stem cell development led us to search for consequences when these genes go wrong,” said Dr. Liu. The team looked for genetic aberrations in nearly 3,000 patients to identify mutations in stem cells that may drive cancer development.

High BCL11A activity happened to be common to 80% of patients with BLBC. “It had all the hallmarks of a novel breast cancer gene,” said Dr. Liu. BCL11A was also associated with advanced tumor grade and poor survival. Continued Dr. Khaled, “Our gene studies in human cells clearly marked BCL11A as a novel driver for TNBC.”

[adrotate group=”3″]

Continuing with these findings, the team “also showed that adding an active human BCL11A gene to human or mouse breast cells in the lab drove them to behave as cancer cells,” according to Dr. Khaled. “As important, when we reduced the activity in BCL11A in three samples of human TNBC cells, they lost some characteristics of cancer cells and became less tumorigenic when tested in mice.” None of the mice with inactivated BCL11A developed tumors when cancer cells were implanted in their mammary glands.

Among TNBC types, BLBC is the most prevalent. None of the three receptor proteins that respond to hormonal treatment is present in BLBC tumors, making treatment especially difficult. New treatments, such as sacituzumab govitecan from Immunomedics, Inc., are being developed to treat these TNBC tumors, and this current  study may help discover additional treatment options that target BCL11A. “By increasing BCL11A activity we increase cancer-like behavior; by reducing it, we reduce cancer-like behavior,” indicated Dr. Khaled.

Print This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged basal-like breast cancer, BCL11A, Dr. Carlos Caldas, Dr. Pentao Liu, Dr. Walid Khaled, gene mutation, triple negative breast cancer.

Post navigation

Previous: Recurrence Risk For Small HER2-Positive Breast Cancer Reduced By Combined Therapy
Next:Novel Technique Shows Promise Against Breast Cancer Brain Metastasis

Recent Posts

  • Enhertu conditional approval U.K.

    Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

    February 22, 2021

  • IRX-2 Phase 2 trial

    Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

    February 18, 2021

  • Tukysa, EU approval

    Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

    February 15, 2021

Featured Post

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

June 30, 2020

Visit Breast Cancer News's profile on Pinterest.

FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers

July 1, 2020

Phesgo approved

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

May 7, 2020

FDA approval

Create your own user feedback survey

Breast Cancer News

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • Subscription Support
  • Publishing Team
  • Leadership
  • Our Values
  • Corrections Policy
  • Contact Us
  • Privacy Policy
  • Terms of Service

Disclaimer:

Breast Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2021 All rights reserved.